Physicians' Academy for Cardiovascular Education

FXIa inhibitor as a promising new anticoagulant drug

3' education - Nov. 23, 2021 - Prof. Jeffrey Weitz, MD

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD

Digital transformation in cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Screening for AF with irregular heart rhythm detection by Fitbit wearables

3' education - Nov. 14, 2021 - Steven Lubitz, MD

Randomized study on effects of coffee consumption on acute physiological changes

3' education - Nov. 14, 2021 - Prof. Gregory Marcus, MD

Ambitious project on use of non-physician providers to control BP

3' education - Nov. 14, 2021 - Prof. Keith Ferdinand, MD

What is the best timing for P2Y12i cessation prior to CABG in patients with ACS?

3' education - Nov. 13, 2021 - Derek So, MD

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD - Online CME

Panel discussion: Measuring inflammation in the coronary circulation

15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD

Statin therapy in COVID-19 patients

5' education - Nov. 8, 2021 - Prof. Maciej Banach, PhD, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

Aspirin use associated with higher risk of incident fatal and non-fatal HF

Literature - Nov. 30, 2021 - Mujaj B et al. - ESC Heart Fail. 2021

This patient-level pooled analysis used data from 30 827 participants at risk of HF and showed that aspirin use was associated with a higher risk of incident fatal and non-fatal HF.

ARNI may reduce total heart failure events in patients with acute MI

Literature - Nov. 30, 2021 - Pfeffer MA, et al. - Circulation 2021

An exploratory analysis of the PARADISE-MI trial suggested that treatment with sacubitril/valsartan after an acute MI may reduce recurrent HF events compared to ramipril.

Dose-dependent reduction of LDL-c levels by CETP-inhibitor

News - Nov. 29, 2021
Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

Phase 2b trial evaluating ANGPTL3 antisense meets primary endpoint

News - Nov. 29, 2021

The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.

Amylin analogue reduces body weight in individuals with overweight and obesity

Literature - Nov. 24, 2021 - Lau DCW, et al. - The Lancet 2021

Treatment with cagrilintide for 26 weeks in individuals with overweight or obesity without T2DM resulted in dose-dependent reduction in bodyweight and waist circumference.

FXIa inhibitor as a promising new anticoagulant drug

3' education - Nov. 23, 2021 - Prof. Jeffrey Weitz, MD
Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.

AHA 2021 Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.

FDA New Drug Application and Priority Review for SGLT2i for HF across the full spectrum of ejection fraction

News - Nov. 23, 2021

The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD
What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.

What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.

New eGFR equations without race

News - Nov. 23, 2021

The use of race in equations to estimate GFR is a subject of discussion. This study developed new eGFR equations that do not include race and compared the performance of current and new eGFR equations.

Reversal of antiplatelet effects of P2Y12i by monoclonal antibody fragment

News - Nov. 22, 2021

AHA 2021 An interim analysis of the REVERSE-IT study showed that administration of bentracimab resulted in immediate and sustained reversal of antiplatelet effect of ticagrelor in patients who present with uncontrolled major or life-threating bleeding or who require urgent surgery or invasive procedures.

Remote program to improve lipid and hypertension management

News - Nov. 22, 2021

AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

Factor XIa inhibitor effective for VTE prevention after knee arthroplasty

News - Nov. 22, 2021

AHA 2021 In a dose-ranging phase 2 study, ≥100 mg per day of the oral factor XIa inhibitor milvexian reduced VTE rate compared to enoxaparin in patients who underwent elective knee replacement surgery.

Agenda